DATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGODATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGO
Home/Compounds/Hexarelin
Growth hormone

Hexarelin

Also known as: Examorelin

Potent GHRP with strong GH release and unique cardioprotective properties.

B
Grade B
Human observational studies
Human studies21
PubMed citations30
Typical dose100 mcg – 200 mcg
Routesubcutaneous
Regulatory (US)Compounding legal
Last verified4 days ago
TL;DR · 30-second summary
  • Very potent GH release
  • Direct cardioprotective effects
  • Faster desensitization than other GHRPs
  • Significant cortisol and prolactin elevation

Mechanism of action

Synthetic hexapeptide ghrelin mimetic with high potency GH release. Uniquely activates cardiac GHS receptors providing direct cardioprotective effects independent of GH.

Evidence summary

21
Human studies
30
PubMed citations
0
Clinical trials
B
Evidence grade

Research shows potent GH release and unique cardiac benefits. Desensitization occurs faster than other GHRPs, limiting continuous use.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Dose range
100 mcg – 200 mcg

100-200mcg 2-3x daily. Cycling recommended due to desensitization (4 weeks on, 4 weeks off).

Administration routes
subcutaneous

Side effects & safety

Reported side effects
Cortisol elevationProlactin increaseWater retentionDecreased insulin sensitivity
Contraindications
  • Active malignancy
  • Hyperprolactinemia

Interactions

No documented drug interactions on file.

Regulatory status

United States
Not FDA approved

Not FDA approved. Research chemical.

Compounding
Permitted

Available through compounding pharmacies with valid prescription.

Regulatory data last verified 4/17/2026

Clinical trials

No indexed ClinicalTrials.gov studies for Hexarelin. This usually means the compound isn't being studied under an IND — check the citations section for peer-reviewed research instead.

Citations

PMID 40465419Pobee E, Daziani G et al. · Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry.Journal of analytical toxicology (2025)HumanPMID 37982184Hossain S, Kneiszl R et al. · Revealing the interaction between peptide drugs and permeation enhancers in the presence of intestinal bile salts.Nanoscale (2023)PMID 36674509Meanti R, Licata M et al. · Protective Effects of Hexarelin and JMV2894 in a Human Neuroblastoma Cell Line Expressing the SOD1-G93A Mutated Protein.International journal of molecular sciences (2023)HumanPMID 34856183Jiang B, Wang M et al. · Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation.Microvascular research (2022)PMID 32893668Baser T, Ozdemir E et al. · Ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats.Canadian journal of physiology and pharmacology (2021)PMID 31091855Agbo E, Liu D et al. · Modulation of PTEN by hexarelin attenuates coronary artery ligation-induced heart failure in rats.Turkish journal of medical sciences (2020)HumanPMID 29756411McDonald H, Peart J et al. · Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction.Physiological reports (2019)HumanPMID 29026190Sirago G, Conte E et al. · Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia.Scientific reports (2019)HumanPMID 28400207Sigalos JT, Pastuszak AW · The Safety and Efficacy of Growth Hormone Secretagogues.Sexual medicine reviews (2018)HumanPMID 25645463Mosa RM, Zhang Z et al. · Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases.Endocrine (2016)HumanPMID 24747279Mao Y, Tokudome T et al. · One dose of oral hexarelin protects chronic cardiac function after myocardial infarction.Peptides (2015)PMID 25278975Mao Y, Tokudome T et al. · The cardiovascular action of hexarelin.Journal of geriatric cardiology : JGC (2014)HumanPMID 18787385Bresciani E, Pitsikas N et al. · Feeding behavior during long-term hexarelin administration in young and old rats.Journal of endocrinological investigation (2008)HumanPMID 18787392Deghenghi R · Hexarelin: a multi-receptor peptide.Journal of endocrinological investigation (2008)HumanPMID 16219302Marleau S, Mulumba M et al. · Cardiac and peripheral actions of growth hormone and its releasing peptides: relevance for the treatment of cardiomyopathies.Cardiovascular research (2006)HumanPMID 16081643Brywe KG, Leverin AL et al. · Growth hormone-releasing peptide hexarelin reduces neonatal brain injury and alters Akt/glycogen synthase kinase-3beta phosphorylation.Endocrinology (2005)PMID 12616707Bayés M, Rabasseda X et al. · Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology (2003)HumanPMID 12379504Pettersson I, Muccioli G et al. · Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation.The Journal of endocrinology (2002)HumanPMID 11238504Arvat E, Maccario M et al. · Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.The Journal of clinical endocrinology and metabolism (2001)HumanPMID 11164389Melis MR, Succu S et al. · Penile erection induced by EP 80661 and other hexarelin peptide analogues: involvement of paraventricular nitric oxide.European journal of pharmacology (2001)

Showing 20 of 30 papers. View all on PubMed →